{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T04:09:09Z","timestamp":1648958949672},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,9,9]],"date-time":"2012-09-09T00:00:00Z","timestamp":1347148800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s12185-012-1168-9","type":"journal-article","created":{"date-parts":[[2012,9,8]],"date-time":"2012-09-08T09:19:05Z","timestamp":1347095945000},"page":"521-524","source":"Crossref","is-referenced-by-count":0,"title":["Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon"],"prefix":"10.1007","volume":"96","author":[{"given":"Zaher K.","family":"Otrock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami A.","family":"Mahfouz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahera","family":"Fahed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi S.","family":"Farhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azzam","family":"Ziade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nader","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel R.","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,9]]},"reference":[{"key":"1168_CR1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330\u201340.","journal-title":"N Engl J Med"},{"key":"1168_CR2","doi-asserted-by":"crossref","unstructured":"Deininger MW. Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program. 2008:419\u201326.","DOI":"10.1182\/asheducation-2008.1.419"},{"key":"1168_CR3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2010.10.018","volume":"300","author":"M Breccia","year":"2011","unstructured":"Breccia M, Efficace F, Alimena G. Imatinib treatment in chronic myelogenous leukemia: what have we learned so far? Cancer Lett. 2011;300:115\u201321.","journal-title":"Cancer Lett"},{"key":"1168_CR4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.26249","volume":"118","author":"FE Nicolini","year":"2012","unstructured":"Nicolini FE, Turkina A, Shen ZX, Gallagher N, Jootar S, Powell BL, et al. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Cancer. 2012;118:118\u201326.","journal-title":"Cancer"},{"key":"1168_CR5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129\u201341.","journal-title":"Cancer Cell"},{"key":"1168_CR6","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"1168_CR7","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117:1141\u20135.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1168-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-012-1168-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1168-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T05:11:06Z","timestamp":1559452266000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-012-1168-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,9]]},"references-count":7,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["1168"],"URL":"https:\/\/doi.org\/10.1007\/s12185-012-1168-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,9]]}}}